{"transactions":[{"id":673504,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-27T20:14:53.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":14036,"price":2.2064,"value":30969.0304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2230052,"source":{"system":"sec-edgar","filing":"0000905148-26-003968","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003968/form4.xml","form_type":"4"}},{"id":679552,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:06.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":484,"price":2.01,"value":972.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":385859,"source":{"system":"sec-edgar","filing":"0000905148-26-003836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003836/form4.xml","form_type":"4"}},{"id":679551,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:06.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1229,"price":2.01,"value":2470.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2244088,"source":{"system":"sec-edgar","filing":"0000905148-26-003836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003836/form4.xml","form_type":"4"}},{"id":763180,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-26T20:09:28.000Z","date":"2026-05-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":13729,"price":1.79,"value":24574.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2245317,"source":{"system":"sec-edgar","filing":"0000905148-26-002652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002652/form4.xml","form_type":"4"}},{"id":769397,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":72706,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":386343,"source":{"system":"sec-edgar","filing":"0000905148-26-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002549/form4.xml","form_type":"4"}},{"id":769396,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":180095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2259046,"source":{"system":"sec-edgar","filing":"0000905148-26-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002549/form4.xml","form_type":"4"}},{"id":774264,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:14.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":1.92,"value":940.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":313637,"source":{"system":"sec-edgar","filing":"0000905148-26-002498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002498/form4.xml","form_type":"4"}},{"id":774263,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:14.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1253,"price":1.92,"value":2405.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2078951,"source":{"system":"sec-edgar","filing":"0000905148-26-002498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002498/form4.xml","form_type":"4"}},{"id":864764,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:15:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":185495,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":185495,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":185495},"source":{"system":"sec-edgar","filing":"0000905148-26-001115","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001115/form4.xml","form_type":"4"}},{"id":864763,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:15:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":417210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":417210,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":417210},"source":{"system":"sec-edgar","filing":"0000905148-26-001115","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001115/form4.xml","form_type":"4"}},{"id":883795,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-24T21:12:46.000Z","date":"2026-02-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":14265,"price":1.53,"value":21825.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2080204,"source":{"system":"sec-edgar","filing":"0000905148-26-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001010/form4.xml","form_type":"4"}},{"id":895592,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-18T21:09:33.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":579,"price":1.63,"value":943.77,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen?s spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":314127,"source":{"system":"sec-edgar","filing":"0000905148-26-000934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000934/form4.xml","form_type":"4"}},{"id":895591,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-18T21:09:33.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1302,"price":1.63,"value":2122.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson?s spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2094469,"source":{"system":"sec-edgar","filing":"0000905148-26-000934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000934/form4.xml","form_type":"4"}},{"id":936696,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-01-16T21:02:48.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":49000,"price":1.676,"value":82124.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2095771,"source":{"system":"sec-edgar","filing":"0000905148-26-000226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000226/form4.xml","form_type":"4"}},{"id":988313,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-25T21:03:56.000Z","date":"2025-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19904,"price":2.3,"value":45779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2046771,"source":{"system":"sec-edgar","filing":"0000905148-25-004179","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004179/form4.xml","form_type":"4"}},{"id":994995,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-18T21:28:44.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":2.24,"value":1097.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":314706,"source":{"system":"sec-edgar","filing":"0000905148-25-004127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004127/form4.xml","form_type":"4"}},{"id":994994,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-18T21:28:44.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59765,"price":2.24,"value":133873.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2066675,"source":{"system":"sec-edgar","filing":"0000905148-25-004127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004127/form4.xml","form_type":"4"}},{"id":1056543,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-25T20:39:41.000Z","date":"2025-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19905,"price":1.32,"value":26274.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2126440,"source":{"system":"sec-edgar","filing":"0000905148-25-003121","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003121/form4.xml","form_type":"4"}},{"id":1063468,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-18T21:14:25.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":1.39,"value":681.1,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":315196,"source":{"system":"sec-edgar","filing":"0000905148-25-003039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003039/form4.xml","form_type":"4"}},{"id":1063467,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-18T21:14:25.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59766,"price":1.39,"value":83074.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2146345,"source":{"system":"sec-edgar","filing":"0000905148-25-003039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003039/form4.xml","form_type":"4"}},{"id":1134719,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-23T20:58:19.000Z","date":"2025-05-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19904,"price":1.15,"value":22889.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2206111,"source":{"system":"sec-edgar","filing":"0000905148-25-001900","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001900/form4.xml","form_type":"4"}},{"id":1144658,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-16T20:16:01.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":491,"price":1.14,"value":559.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":315686,"source":{"system":"sec-edgar","filing":"0000905148-25-001820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001820/form4.xml","form_type":"4"}},{"id":1144657,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-16T20:16:01.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59766,"price":1.14,"value":68133.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2226015,"source":{"system":"sec-edgar","filing":"0000905148-25-001820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001820/form4.xml","form_type":"4"}},{"id":1225880,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T22:11:43.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":140540,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":140540,"derivative":{"exercise_price":5.31,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":140540},"source":{"system":"sec-edgar","filing":"0000905148-25-000828","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000828/form4.xml","form_type":"4"}},{"id":1225879,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T22:11:43.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":390390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":390390,"derivative":{"exercise_price":5.31,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":390390},"source":{"system":"sec-edgar","filing":"0000905148-25-000828","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000828/form4.xml","form_type":"4"}},{"id":1245118,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-02-25T21:09:41.000Z","date":"2025-02-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19904,"price":5.54,"value":110268.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2285781,"source":{"system":"sec-edgar","filing":"0000905148-25-000764","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000764/form4.xml","form_type":"4"}},{"id":1258468,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-02-19T21:52:40.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":579,"price":5.42,"value":3138.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":316177,"source":{"system":"sec-edgar","filing":"0000905148-25-000725","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000725/form4.xml","form_type":"4"}},{"id":1258467,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-02-19T21:52:40.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":37152,"price":5.42,"value":201363.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2305685,"source":{"system":"sec-edgar","filing":"0000905148-25-000725","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000725/form4.xml","form_type":"4"}},{"id":1348787,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T23:04:01.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":90090,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":90090,"derivative":{"exercise_price":5.7,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90090},"source":{"system":"sec-edgar","filing":"0000905148-24-003287","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003287/form4.xml","form_type":"4"}},{"id":1348786,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T23:04:01.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":225226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":225226,"derivative":{"exercise_price":5.7,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":225226},"source":{"system":"sec-edgar","filing":"0000905148-24-003287","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003287/form4.xml","form_type":"4"}},{"id":1352300,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2024-11-25T21:29:31.000Z","date":"2024-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19910,"price":6.44,"value":128220.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2342837,"source":{"system":"sec-edgar","filing":"0000905148-24-003270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003270/form4.xml","form_type":"4"}},{"id":1361252,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2024-11-18T21:26:54.000Z","date":"2024-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":7.92,"value":3880.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":316756,"source":{"system":"sec-edgar","filing":"0000905148-24-003223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003223/form4.xml","form_type":"4"}},{"id":1361251,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2024-11-18T21:26:54.000Z","date":"2024-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59766,"price":7.92,"value":473346.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2362747,"source":{"system":"sec-edgar","filing":"0000905148-24-003223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003223/form4.xml","form_type":"4"}},{"id":1423971,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2024-08-23T20:11:28.000Z","date":"2024-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":79616,"price":9.19,"value":731671.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse.  Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2422513,"source":{"system":"sec-edgar","filing":"0000905148-24-002335","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824002335/form4.xml","form_type":"4"}},{"id":1430834,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-16T20:47:45.000Z","date":"2024-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59765,"price":7.02,"value":419550.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":2502129,"source":{"system":"sec-edgar","filing":"0000905148-24-002277","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824002277/form4.xml","form_type":"4"}},{"id":1513692,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-16T22:54:44.000Z","date":"2024-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":54918,"price":8.36,"value":459114.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":2561894,"source":{"system":"sec-edgar","filing":"0000905148-24-001483","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001483/form4.xml","form_type":"4"}},{"id":1637422,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-16T22:06:48.000Z","date":"2024-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":41861,"price":3.4,"value":142327.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":2616812,"source":{"system":"sec-edgar","filing":"0000905148-24-000760","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824000760/form4.xml","form_type":"4"}},{"id":1738555,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-17T00:41:11.000Z","date":"2023-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":239023,"price":5.08,"value":1214236.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":2658673,"source":{"system":"sec-edgar","filing":"0000905148-23-001472","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514823001472/form4.xml","form_type":"4"}},{"id":1798346,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-23T20:19:55.000Z","date":"2023-08-21","kind":"grant","planned":false,"acquired":true,"shares":493994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":2897696,"source":{"system":"sec-edgar","filing":"0000905148-23-000783","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514823000783/form4.xml","form_type":"4"}},{"id":1871582,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T00:40:34.000Z","date":"2023-05-31","kind":"exercise","planned":false,"acquired":false,"shares":33605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date for these options was inadvertently reported as April 5, 2032 on the Form 3 filed by the Reporting Person on November 9, 2022, and has been corrected as of this Form 4."}],"balance_after":90855,"derivative":{"exercise_price":3.88,"expiration_date":"2032-03-22","underlying":"Common Stock","underlying_shares":33605},"source":{"system":"sec-edgar","filing":"0001140361-23-027860","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123027860/form4.xml","form_type":"4"}},{"id":1871581,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-02T00:40:34.000Z","date":"2023-05-31","kind":"exercise","planned":false,"acquired":true,"shares":33605,"price":3.88,"value":130387.4,"ownership":{"direct":true},"balance_after":2403702,"source":{"system":"sec-edgar","filing":"0001140361-23-027860","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123027860/form4.xml","form_type":"4"}},{"id":2114009,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":80120,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":80120,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":80120},"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}},{"id":2114008,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":180269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":180269,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":180269},"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}},{"id":2114007,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":26707,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":320705,"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}},{"id":2114006,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":60090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":2370097,"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}},{"id":2114005,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":503419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 1.885% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering, meant to cover estimated tax liability at the time of settlement of the RSU award referred to in footnote 1."}],"balance_after":2310007,"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}},{"id":2114004,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-17T00:05:47.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":934731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 3.5% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering."}],"balance_after":1806588,"source":{"system":"sec-edgar","filing":"0001209191-22-057395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057395/doc4.xml","form_type":"4"}}]}